Cipla Ltd (BOM:500087) reports robust financial performance with significant milestones in India and strategic advancements in the US market.

Cipla consolidated net profit for the quarter ending June 2025 at ₹1291.61 crore was up 10% compared to ₹1175.46 crore in the ...

Cipla share price gain 3% after Q1 earnings beat estimates, with strong margins, India growth, and positive analyst sentiment ...

The Sensex fell 721 points and the Nifty 50 dropped 225 points amid foreign fund withdrawals. Analysts predict upcoming earnings reports will influence market trends. Cipla, Bajaj Finserv, and BSE are ...

Cipla is looking at the whole GLP-1 category and not just Semaglutide alone, says Cipla CEO Umang Vohra in a post-results ...

Cipla reported a 10% increase in consolidated profit after tax, reaching ₹1,298 crore for Q1 FY26, driven by strong sales in ...

Cipla reports a 10% YoY rise in Q1FY26 net profit, driven by strong performance in consumer healthcare and generics. The ...

Indian drugmaker, Cipla Ltd, sees GLP-1 drugs, used to treat type-2 diabetes and obesity, as a significant new therapy opportunity in the Indian market.

Indian pharmaceutical company, Cipla, aims to reach $1 billion in US sales by FY27, driven by upcoming product launches.

Mumbai-based pharmaceutical major Cipla has reported its financial results for the April-June period, with a ...

Cipla , India's No. 3 drugmaker by sales, reported a first-quarter profit that beat market expectations on Friday.